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Abstract 
Background: Rapid diagnostic tests (RDTs) for histidine rich protein 2 (HRP2) are often used to determine whether 
persons with fever should be treated with anti-malarials. However, Plasmodium falciparum parasites with a deletion of 
the hrp2 gene yield false-negative RDTs and there are concerns the sensitivity of HRP2-based RDTs may fall when the 
intensity of transmission decreases.
Methods: This observational study enrolled 9226 patients at three health centres in Rwanda from April 2014 to April 
2015. It then compared the sensitivity of RDTs based on HRP2 and the Plasmodium lactate dehydrogenase (pLDH) to 
microscopy (thick smears) for the diagnosis of malaria. PCR was used to determine whether deletions of the histidine-
rich central repeat region of the hrp2 gene (exon 2) were associated with false-negative HRP2-based RDTs.
Results: In comparison to microscopy, the sensitivity and specificity of HRP2- and pLDH-based RDTs were 89.5 and 86.2% 
and 80.2 and 94.3%, respectively. When the results for both RDTs were combined, sensitivity rose to 91.8% and specificity 
was 85.7%. Additionally, when smear positivity fell from 46 to 3%, the sensitivity of the HRP2-based RDT fell from 88 to 67%. 
Of 370 samples with false-negative HRP2 RDT results for which PCR was performed, 140 (38%) were identified as P. falcipa-
rum by PCR. Of the isolates identified as P. falciparum by PCR, 32 (23%) were negative for the hrp2 gene based on PCR. Of 
the 32 P. falciparum isolates negative for hrp2 by PCR, 17 (53%) were positive based on the pLDH RDT.
Conclusion: This prospective study of RDT performance coincided with a decline in the intensity of malaria transmis-
sion in Kibirizi (fall in slide positivity from 46 to 3%). This decline was associated with a decrease in HRP2 RDT sensitivity 
(from 88 to 67%). While P. falciparum isolates without the hrp2 gene were an important cause of false-negative HRP2-
based RDTs, most were identified by the pLDH-based RDT. Although WHO does not recommend the use of combined 
HRP2/pLDH testing in sub-Saharan Africa, these results suggest that combination HRP2/pLDH-based RDTs could 
reduce the impact of false-negative HRP2-based RDTs for detection of symptomatic P. falciparum malaria.
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Background
Rapid diagnostic tests (RDTs) have become the focal 
point of malaria control. The central role of RDTs is the 
result of a recent paradigm shift in malaria case manage-
ment, based on the World Health Organization (WHO) 
2010 recommendation that all persons thought to have 
malaria should have their diagnosis confirmed by micros-
copy or an RDT before treatment [1]. However, the value 
of a “test before you treat” policy depends on accurate 
diagnosis. False-negative tests may delay the provision 
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of life-saving treatment for individual patients and may 
simultaneously increase the number of persons capable 
of infecting mosquitoes in the community.
Although microscopy has been used most commonly 
to detect malaria parasites, it requires equipment, rea-
gents and skilled microscopists [2]. Thus, in parts of sub-
Saharan Africa where microscopy is inaccessible or of 
low quality, RDTs have become the primary tool for the 
parasitologic diagnosis or confirmation of malaria [3, 4]. 
Since 2005, the proportion of suspected malaria cases 
examined using a diagnostic test (microscopy or RDT) 
in sub-Saharan Africa rose from 36% in 2005 to 41% in 
2010 and 65% in 2014. In 2014, RDTs accounted for 71% 
of the diagnostic tests performed in sub-Saharan Africa 
[3]. Given the central role RDTs now play in determining 
whether persons with symptoms have malaria and should 
be treated, it is increasingly important to understand the 
factors that influence their performance.
RDTs are immunochromatographic tests which detect 
proteins released from parasitized red blood cells. Most 
of the RDTs used currently to diagnose P. falciparum 
infections target HRP2 [5]. HRP2-based RDTs are spe-
cific for P. falciparum because P. falciparum is the only 
human parasite that produces HRP2 [3]. In contrast, 
RDTs targeting pan-lactate dehydrogenase (pLDH) or 
aldolase can detect all the Plasmodium species that infect 
humans, although they are reported to be less sensitive 
than HRP2-based tests, especially with low parasite den-
sities [6, 7]. In regions where P. falciparum predominates 
and non-falciparum infections occur as mixed infections 
with P. falciparum, including most of sub-Saharan Africa, 
WHO generally recommends HRP2-based RDTs. In con-
trast, pLDH and aldolase-based RDTs are recommended 
in areas where non-falciparum infections predominate. 
Currently, WHO suggests restricting combined HRP2/
pLDH RDTs to regions where P. falciparum and non-fal-
ciparum infections occur as single-species infections [5].
Although the sensitivity of HRP2-based RDTs has 
been reported as >90% for P. falciparum, several groups 
have reported decreases in the sensitivity of HRP2-based 
RDTs after decreases in the intensity of transmission 
[7–9]. For example, in Zanzibar, the sensitivity of HRP2-
based RDTs in relation to thick smears fell from 93 to 
79% as the percent of malaria-attributable fever episodes 
in the population decreased from 30 to <3% [9].
Plasmodium falciparum parasites without the central 
repeat region of the hrp2 gene may cause false-negative 
RDTs [10, 11] because they fail to produce the HRP2 
target molecule for HRP2-based RDTs. Isolates with 
hrp2-negative P. falciparum have now been identified in 
the blood of infected human subjects in South America, 
Asia and Africa [10–13]. However, despite the diagnostic 
threat and malaria control concerns posed by parasites 
without hrp2, there is a paucity of data on the frequency 
of those parasites and the factors driving (responsible for) 
their selection.
Preliminary studies from Mali have found seasonal 
fluctuations in the prevalence of false-negative RDTs and 
suggest the peak prevalence of hrp2-negative isolates is 
at the end of the dry season [8]. However, it is not clear 
whether the seasonal variation in RDT sensitivity for 
P. falciparum infection observed in Mali occurs in East 
Africa or elsewhere. There is also a need to determine 
whether hrp2-negative parasites can be identified using 
pLDH-based RDTs.
To address these knowledge gaps, this study com-
pared the sensitivities of HRP2- and pLDH-based RDTs 
at sites with varying intensities of malaria transmission 
in Rwanda to determine whether deletions of hrp2 were 
responsible for false-negative HRP2-based RDTs.
Methods
Study design and sites
This cross-sectional study was conducted at three pri-
mary health centres in Rwanda: Busogo Health Centre 
(HC) in the Musanze district of the Northern Province, 
Rukara HC in the Kayonza district of the Eastern Prov-
ince and Kibirizi HC in the Gisagara district of the South-
ern Province (Fig. 1). These health centres were selected 
to provide sites with varying prevalences of infection 
consistent with different intensities of transmission. For 
example, in 2013, slide positivity rates for symptomatic 
patients were 32.0, 10.8 and 3.5% for the Kibirizi, Rukara 
and Busogo HCs, respectively [14]. Historically, malaria 
transmission has occurred year-round in Rwanda’s 
endemic regions with two peaks (May–June and Novem-
ber–December) after seasonal rains in March–April 
and September–October. Plasmodium falciparum is the 
Fig. 1 Study sites and household-level parasite prevalence in chil-
dren under 5 years of age, by province. Parasite prevalence data from 
2014 to 2015 DHS [16]. Asterisk notes the city of Kigali with a parasite 
prevalence of 0.0%. HC health center
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predominant parasite and mosquitoes of the Anopheles 
gambiae complex are the primary vectors.
The major malaria control interventions in Rwanda are 
long-lasting insecticidal nets (LLINs) impregnated with 
pyrethroids, indoor residual spraying (IRS) with carba-
mates and prompt treatment of confirmed cases with 
artemisinin-based combination therapy (artemether–
lumefantrine) [15]. Between 2009 and 2011, over 6.1 
million LLINs were distributed in Rwanda (total popu-
lation 10.5 million) with the goal of achieving universal 
coverage. Subsequently, the 2014–2015 Rwandan Demo-
graphic and Health Survey (DHS) found 83% of house-
holds owned at least one treated bed net and 43% of 
households had one net for every two people sleeping in 
the house [16]. IRS has also been implemented in districts 
selected by the Malaria and Other Parasitic Diseases 
Division (MOPDD) of the Ministry of Health including 
Gisagara, where the Kibirizi HC is located. During this 
study, two rounds of IRS (September/ October 2014 and 
February/March 2015) were performed in Kibirizi and 
coverage was reported to be greater than 98% [15]. For 
patients with uncomplicated malaria, artemether–lume-
fantrine has been the first-line treatment in Rwanda since 
2006.
Patient enrollment and study procedures
Convenience sampling was used to enroll patients who 
presented to these three health centres with symptoms 
consistent with uncomplicated malaria and were referred 
to the outpatient laboratory for blood smears in accord-
ance with Rwanda malaria treatment guidelines. Study 
personnel were not involved in the decision to refer 
patients to the laboratory. Patients were excluded from 
this study if they were diagnosed as having severe malaria 
or other conditions requiring urgent diagnosis or treat-
ment. Eligible patients were recruited Monday to Friday 
from 8 a.m. to 4 p.m.
At the time of enrollment, demographic and clini-
cal information was collected and a finger-prick blood 
sample was obtained for thick and thin blood smears, an 
RDT and filter paper blots which were stored for molecu-
lar testing. Study personnel were experienced nurses and 
laboratory technicians trained in the performance and 
interpretation of blood smears and RDTs for malaria.
Laboratory procedures
Rapid diagnostic tests
The RDT used in this study was the First Response® 
Malaria pLDH/HRP2 Combo test (Premier Medi-
cal Corporation Limited, India; catalogue number 
I16FRC) which was provided by the Rwandan Ministry 
of Health. This RDT uses a buffer solution containing 
dye-labelled monoclonal antibodies to HRP2 and pLDH. 
The antigen–antibody complexes are then captured by 
monoclonal antibodies to the target antigens, which are 
immobilized on the test strip. The combo test has three 
lines of immobilized antibodies on the test strip: a spe-
cies-specific antibody for P. falciparum HRP2, a genus 
(Plasmodium)-specific antibody for pLDH at a different 
position on the test strip and a control antibody at a third 
position. Testing was performed and interpreted accord-
ing to the manufacturer’s instructions in the package 
insert. Faint bands at the test line positions were inter-
preted as positive [9, 17].
Microscopy
Thick and thin blood smears were collected on the 
same slide, air-dried and stained with 10% Giemsa for 
10 min after the thin smears had been fixed with meth-
anol. Thick smears were examined under oil immersion 
(1000× magnification) by two independent laboratory 
technicians. Asexual parasitaemia at any parasite den-
sity was reported as a positive smear. Blood smears were 
considered negative if no parasites were observed after 
the examination of 100 oil immersion fields. Disparities 
in slide readings (positive vs negative) and differences 
>30% in parasite densities were resolved by a third reader. 
Note that study microscopists did not have access to the 
subjects’ RDT results or previous microscopy results. All 
laboratory technicians were qualified at the diploma level 
or above in the medical laboratory sciences.
Filter paper blots
Blood samples collected on filter paper (Whatman 3 
MM) were air-dried thoroughly, placed in individual 
sealed plastic bags with desiccant and stored at room 
temperature prior to molecular analysis by PCR.
Amplification of the central repeat region of the hrp2 gene 
(exon 2) and 18S rRNA parasite DNA sequences
PCR was performed to test for Plasmodium DNA in sam-
ples that were negative using the HRP2 RDT but posi-
tive by microcopy or the pLDH RDT. Within 3  months 
of sample collection, DNA was isolated from dried blood 
spots on filter papers using six 3  mm punches and the 
QIAamp DNA mini kit (Qiagen, Germantown, MD). 
Positive and negative controls were used with each round 
of PCR. After PCR, amplicons were visualized by elec-
trophoresis using 2% agarose gels stained with ethidium 
bromide.
PCR protocol
A sequential, 3-step approach to PCR was used to assign 
each sample to one of four categories: (1) DNA from P. fal-
ciparum with the hrp2 gene, (2) DNA from P. falciparum 
without the central histidine-rich repeat region of the hrp2 
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gene, (3) DNA from Plasmodium other than P. falciparum 
and (4) samples without Plasmodium DNA. This stepwise 
protocol is depicted in Fig. 2 and described below.
For samples negative with the HRP2 RDT but posi-
tive by microcopy or the pLDH RDT, primers for the 
conserved 5′ and 3′ regions of the hrp2 gene (Additional 
file  1: Table S1) were used to amplify the histidine-rich 
central repeat region of the hrp2 gene [10]. Samples posi-
tive for the hrp2 gene with this PCR were designated as P. 
falciparum with the hrp2 gene and no further PCR test-
ing was performed.
Samples PCR-negative for the hrp2 gene were exam-
ined by PCR using primers for conserved regions of P. fal-
ciparum 18S rRNA [18, 19]. Samples positive in this PCR 
for Pf 18S rRNA were designated as P. falciparum with-
out the hrp2 gene and no further testing was performed.
In contrast, samples negative for P. falciparum 18S 
rRNA were re-examined by PCR using primers for 
conserved regions of 18S rRNA in Plasmodium vivax, 
Plasmodium malariae and Plasmodium ovale [18, 19]. 
Samples positive using primers for 18S rRNA from P. 
vivax, P. malariae or P. ovale were designated non-P. 
falciparum malaria parasites and no further testing was 
performed. Samples negative in this PCR were consid-
ered negative for Plasmodium DNA and no further test-
ing was performed.
The primers used are listed in Additional file  1 and a 
sample gel is presented in Additional file 2. Because the 
prevalence of non-falciparum Plasmodium parasites 
was greater than anticipated, amplification of 18S rRNA 
was changed from nested PCR described by Singh et al. 
[19] to multiplex PCR capable of detecting P. falcipa-
rum, P. vivax, P. malariae and P. ovale in a single-round 
of amplification to minimize the number of rounds of 
amplification required for species identification [18]. 
Primers targeting 18S rRNA have been reported to detect 
parasitemia at parasite densities as low as 1 parasite per 
microlitre [18, 20].
Statistical methods
Microsoft Excel was used for data entry and Stata (ver-
sion 13) for analysis. The sensitivity, specificity and 
positive and negative predictive values of the HRP2 
and pLDH RDTs were compared to microscopy (thick 
smears) which was used as the reference standard. RDT 
results were considered true positives or true nega-
tives if they were concordant with microscopy. Negative 
RDT results were considered false-negatives if micros-
copy was positive. Positive RDTs were considered false-
positives if microscopy was negative. Differences with a 
probability of less than 0.05 (P < 0.05) were accepted as 
significant.
Fig. 2 PCR amplification of samples negative with the HRP2 RDT which were positive by microscopy or by pLDH RDT. PCR was performed to test 
for Plasmodium DNA in samples that were negative by HRP2 RDT but positive by either microcopy or by pLDH RDT. PCR was performed using a 
tiered, 3-stage approach. Rows 2–4 of the flowchart reflect PCR performed in stages 1–3, respectively. The primers used at each stage are listed in 
the gray boxes to the right of the flowchart. If a sample was identified as positive by PCR at any stage, no further PCR testing was pursued. Samples 
positive by PCR for the hrp2 gene were considered P. falciparum isolates containing the hrp2 gene. Samples negative by PCR for the hrp2 gene and 
positive by PCR for Pf 18S rRNA were considered P. falciparum isolates lacking the hrp2 gene. Samples negative by PCR for the hrp2 gene and Pf 18S 
rRNA but positive by PCR for Pv, Pm or Po 18S rRNA were considered non-Pf malaria. Samples negative by PCR for the hrp2 gene, Pf 18S rRNA and Pv, 
Pm and Po 18S rRNA were considered negative for Plasmodium DNA. Pf Plasmodium falciparum, Pv P. vivax, Pm P. malariae, Po P. ovale
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Results
The flow of patients through the study is outlined in 
Fig. 3 and Table 1 provides a summary of baseline charac-
teristics for the patients enrolled at each site. Of the 9226 
patients screened, seven did not provide informed con-
sent for their participation. Of the 9219 patients who con-
sented to participate in the study, 462 were not included 
in the analysis because of incomplete test results (invalid 
or unrecorded RDT or microscopy results, other miss-
ing data or unreadable blood smears). Thus, 8757 sets 
of paired RDT and microscopy results for 8757 patients 
were included in the analysis (Fig. 3).
Study sites
Patients were enrolled from three sites across Rwanda 
which vary in malaria endemicity. When the study sites 
were selected, malaria transmission was believed to be 
lowest in Busogo and highest in Kibirizi. The rationale for 
enrolling subjects in Kibirizi for 12 months was to deter-
mine whether RDT sensitivity varied seasonally. However, 
Kibirizi HC is within a district targeted for IRS by Rwan-
da’s MOPDD and two rounds of IRS were performed in 
Kibirizi during this study: in September 2014 and Febru-
ary 2015. Overall, the fractions of referred patients with 
positive thick smears for Plasmodium species were 10% 
(87/913) at Busogo, 35% (1778/5148) at Kibirizi and 53% 
(1426/2696) at Rukara. At the Kibirizi HC, the monthly 
slide positivity rate declined from 46% in April 2014 to 3% 
in April 2015 after two rounds of IRS (Fig. 4).
Sensitivity and specificity: HRP2 RDT vs combined 
HRP2 + pLDH RDT
Among the 8757 patients for whom microscopy and RDT 
test results were available, 3291 (38%) were positive for 
Fig. 3 Laboratory results for patients enrolled at all three health centers. Samples positive by PCR targeting the hrp2 gene were labelled hrp2 pos 
Pf, samples negative by PCR targeting the hrp2 gene and positive by PCR targeting Pf 18S rRNA were labelled hrp2 neg Pf, samples negative by PCR 
targeting the hrp2 gene and Pf 18S rRNA but positive by PCR targeting Pv, Pm or Po 18S rRNA were labelled non-Pf and samples negative by PCR 
targeting the hrp2 gene, Pf 18S rRNA and Pv, Pm and Po 18S rRNA were labelled negative. Pf Plasmodium falciparum, Pv P. vivax, Pm P. malariae, Po P. 
ovale, RDT rapid diagnostic test, HRP2 histidine rich protein 2, pLDH Plasmodium lactate dehydrogenase, PCR polymerase chain reaction, Pf Plasmo-
dium falciparum, non-Pf non-Plasmodium falciparum
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Plasmodium species by thick smear. Among those speci-
mens, the HRP2 RDT identified 2944 positives and the 
pLDH-based RDT identified 2639 positives. The overall 
sensitivities and specificities of the RDTs in comparison 
to microscopy were 89.5% (95% confidence interval [CI] 
88.4–90.5) and 86.2% (95% CI 85.2–87.1) for the HRP2 
RDT and 80.2% (95% CI 78.8–81.5) and 94.3% (95% CI 
93.7–94.9) for the pLDH RDT, respectively. The pLDH 
RDT detected 78 microscopy-positive samples that were 
missed by the HRP2 RDT. Thus, when the pLDH RDT 
results were considered with the HRP2 RDT results, RDT 
sensitivity increased from 89.5 to 91.8% (95% CI 90.8–
92.7) and there was no significant difference (P = 0.29) in 
RDT specificity. When the HRP2 and pLDH RDTs were 
considered together, RDT specificity was 85.7% (95% CI 
84.7–86.6) (Table 2).
Variation in sensitivity of the HRP2 RDT and the slide 
positivity rate
Variations in the sensitivity of the HRP2 RDT were noted 
by site and month (Fig.  4). The sensitivity of the HRP2 
RDT was greatest at Rukara (90–97%), the site with the 
highest fraction of positive blood smears (slide positiv-
ity rate). In contrast, at Kibirizi, when the smear positiv-
ity rate decreased from 55% in June 2014 to 3% in April 
2015, the sensitivity of the HRP2 RDT fell from 93 to 67% 
(Chi square for trend = 37.2, P < 0.001). At Busogo, the 
monthly sensitivity of the HRP2 RDT ranged from 71 to 
93% (Chi square for trend = 0.4, P = 0.522).
False‑negative HRP2 RDTs and PCR for the hrp2 gene
PCR studies were performed for 343 of the 347 samples 
with false-negative HRP2 RDTs (Fig. 3). Of the 343 sam-
ples examined, Plasmodium DNA was detected using 
primers for the histidine-rich central repeat region of the 
hrp2 gene or conserved loci in Plasmodium 18S rRNA 
[10, 18, 19] in 322 (94%) of samples. Of these 322 sam-
ples, 138 (43%) were positive by PCR for P. falciparum 
DNA using primers for the histidine-rich central repeat 
region of the hrp2 gene or P. falciparum 18S rRNA and 
184 (57%) were positive only by PCR for 18S rRNA from 
non-falciparum species. Of the 138 P. falciparum samples 
with false-negative RDTs, 106 (77%) were positive for the 
P. falciparum hrp2 gene and 32 (23%) were negative on 
Table 1 Baseline characteristics
EIR entomological inoculation rate, IRS indoor residual spraying, CI confidence 
interval, SPR slide positivity rate
a EIR defined as the number of infective Anopheles mosquito bites per person 
per year
b Data provided from closest sentinel site, Bungwe (no sentinel site in Busogo 
HC’s district)
Characteristic Sites
Kibirizi
n = 5148
Rukara
n = 2696
Busogo
n = 913
Altitude (m) 1718 1591 2247
Average annual rain-
fall (mm) [36]
81 75 129
EIRa [15] – 20.9 <1b
IRS with carbamates Sep ‘14; Feb ‘15
Dates of study Apr ‘14–Apr ‘15 Oct ‘14–Mar ‘15 Nov ‘14–Apr ‘15
Mean age (95% CI) 22.3 (21.7–22.8) 20.8 (20.1–21.5) 20.5 (19.5–21.6)
Age <5 years, % 
(95% CI)
19.4 (18.4–20.6) 17.5 (16.2–19.0) 22.3 (19.8–25.2)
SPR if age <5 years, 
% (95% CI)
32.1 (29.1–35.1) 41.6 (37.2–46.1) 2.4 (0.3–4.6)
SPR if age ≥5 years, 
% (95% CI)
36.0 (34.5–37.5) 55.3 (53.2–57.4) 11.6 (9.2–13.9)
Fig. 4 HRP2 RDT sensitivity, slide positivity rate and rainfall by study 
site and month. Rainfall is plotted in millimeters per month on the left 
y axis. Sensitivity and slide positivity rate are plotted on the right y axis. 
The navy band represents the 95% confidence interval for sensitiv-
ity. The dashed line represents the slide positivity rate. There was 
significant variation in HRP2 RDT sensitivity across the study sites and 
a decline in RDT sensitivity was noted following a decline in malaria 
transmission. In Rukara, monthly estimates of HRP2 RDT sensitivity 
ranged from 90 to 97%. Conversely, in Kibirizi, a site subject to two 
rounds of IRS during the study period, the sensitivity of the HRP2 RDT 
declined from 88 to 67% as the slide positivity rate fell from 46 to 3%. 
SPR slide positivity rate; CI confidence interval
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PCR for the central repeat region of the hrp2 gene but 
positive for P. falciparum 18S rRNA (consistent with 
hrp2 deletion).
In Kibirizi, PCR for the hrp2 gene was negative for 
26 of the 110 (24%) of the P. falciparum infections with 
false-negative RDTs and the proportion of hrp2-nega-
tive isolates did not increase as the slide positivity rate 
decreased (Fig. 5).
pLDH RDT detection of samples with false‑negative HRP2 
RDTs
The pLDH RDT was positive for 41 of the 138 (30%) P. 
falciparum infections with false-negative HRP2 RDTs. 
Notably, the pLDH RDT was positive for the majority 
(53%) of the P. falciparum samples with false-negative 
HRP2 RDTs that were negative by PCR for the hrp2 gene.
pLDH RDT results for samples positive by microscopy
In Kibirizi, the proportion of microscopy positive sam-
ples that were negative by pLDH RDT increased as slide 
positivity decreased (Fig.  6). The proportion of micros-
copy positive and pLDH negative samples rose from 
13.9% (95% CI 12.7–16.0) during April to August 2014 to 
38.6% (95% CI 32.1–45.6) during December 2014 to April 
2015.
pLDH RDT positive samples negative by microscopy 
and HRP2 RDT
PCR studies were also performed on 27 samples posi-
tive the pLDH RDT but negative by microscopy and the 
HRP2 RDT. Of these 27 samples, 2 were positive by PCR 
for hrp2 and 9 were positive only by PCR for 18S rRNA 
from non-falciparum species.
Discussion
In sub-Saharan Africa, HRP2 RDTs are the test used 
most commonly for parasitologic confirmation of malaria 
before treatment [5]. However, several reports have noted 
significant declines in the sensitivity of HRP2 RDTs after 
declines in the intensity of transmission [7–9]. In Mali, 
preliminary studies found seasonal declines in RDT 
sensitivity were associated with peaks in the prevalence 
of hrp2-negative P. falciparum isolates at the end of the 
dry season [8]. It is not clear if the association between 
declining RDT sensitivity and increasing prevalence of 
hrp2-negative isolates observed in Mali occurs elsewhere.
Thus, this study compared the sensitivity of HRP2 
RDTs at 3 sites with varying intensities of transmission 
in Rwanda to determine whether deletions of hrp2 were 
responsible for false-negative HRP2-based RDTs. RDT 
performance was examined in relation to microscopy 
Table 2 RDT sensitivity and specificity for the diagnosis of malaria compared to microscopy as the gold standard
CI confidence interval, RDT rapid diagnostic test, HRP2 histidine rich protein 2, pLDH Plasmodium lactate dehydrogenase
RDT target Sensitivity, % (95% CI) All sites
Kibirizi Rukara Busogo
HRP2 RDT 86.2 (84.5–87.8) 93.6 (92.2–94.8) 87.4 (78.5–93.5) 89.5 (88.9–90.0)
pLDH RDT 81.4 (79.5–83.2) 79.9 (77.8–82) 59.8 (48.7–70.1) 80.2 (79.5–80.9)
HRP2 + pLDH RDT 90.5 (89.0–91.8) 93.8 (92.4–95.0) 87.4 (78.5–93.5) 91.8 (91.3–92.3)
RDT target Specificity, % (95% CI) All sites
Kibirizi Rukara Busogo
HRP2 RDT 84.7 (83.5–85.9) 83.4 (81.2–85.4) 96.2 (94.7–97.4) 86.2 (85.7–86.6)
pLDH RDT 92.7 (91.8–93.6) 95.4 (94.1–96.5) 99.0 (98.1–99.6) 94.3 (94.0–94.6)
HRP2 + pLDH RDT 84.0 (82.7–85.2) 83.3 (81.1–85.3) 96.2 (94.7–97.4) 85.7 (85.2–86.1)
Fig. 5 hrp2 PCR for P. falciparum isolates with false-negative HRP2 
RDTs. Of the 138 P. falciparum samples with false-negative HRP2 RDTs, 
106 were positive by PCR for the P. falciparum hrp2 gene (light blue 
bars) and 32 were negative by PCR for the central repeat region of the 
hrp2 gene (black bars). In Kibirizi, improved malaria control was not 
associated with an increased frequency of false-negative RDTs due to 
hrp2-negative P. falciparum isolates
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which was considered the gold standard. Samples with 
false-negative HRP2 RDTs (positive smear, negative 
RDT) were re-examined using PCR to test for the hrp2 
gene.
Consistent with previous reports, this study found 
that HRP2-based RDTs were more sensitive than pLDH-
based RDTs, although less specific [6, 7, 17]. How-
ever, when the HRP2 and pLDH RDTs were considered 
together, sensitivity increased slightly, without a decline 
in specificity. Using both RDTs, sensitivity was 91.8% and 
specificity was 85.7%.
Notably, the sensitivity of HRP2-based RDTs varied 
across the study sites and there was a decrease in the 
sensitivity of the HRP2 RDT after a fall in malaria trans-
mission. In Rukara, monthly estimates of HRP2 RDT 
sensitivity ranged from 90 to 97%. Conversely, in Kibirizi, 
the sensitivity of the HRP2 RDT declined from 88 to 67% 
after two rounds of IRS as slide positivity rate for symp-
tomatic patients fell from 46 to 3%.
Although IRS appeared to reduce the incidence of 
malaria in Kibirizi, a recent study in an area of The Gam-
bia with high LLIN coverage found no additional benefit 
from adding IRS. Of note, in The Gambia, ≥93% LLIN 
coverage was achieved for all sleeping spaces and IRS 
coverage was 83–86%. [21]. In contrast, the 2014–2015 
Rwandan DHS found that IRS achieved >98% coverage of 
targeted areas while only 81% of households had at least 
one LLIN and 43% of households had an LLIN for every 
two persons [16].
Potential explanations for false-negative HRP2 RDTs 
and the decline of RDT sensitivity in Kibirizi include: loss 
(deletion) of the hrp2 gene and low parasite densities [6, 
10, 11].
Parasites lacking the hrp2 gene are a potential source of 
false-negative HRP2 RDTs. The hrp2 gene is absent in P. 
falciparum isolates with hrp2 gene deletions and in non-
falciparum Plasmodium parasites. PCR analysis was used 
to identify isolates without the hrp2 gene and to confirm 
the presence P. falciparum DNA. Of 138 P. falciparum 
infections with false-negative HRP2 RDTs, 32 were nega-
tive by PCR for hrp2 (consistent with deletion of the hrp2 
gene).
Plasmodium falciparum isolates lacking the hrp2 gene 
appear to be a significant source of false-negative RDTs 
in Rwanda. However, in this study, most P. falcipa-
rum isolates lacking the hrp2 gene were detected by the 
pLDH-based RDT and improved malaria control was not 
associated with an increased frequency of false-negative 
RDTs due to hrp2-negative P. falciparum isolates (Fig. 5).
For the majority (106/138  =  77%) of P. falciparum 
samples with false-negative HRP2 RDT results, PCR for 
hrp2 was positive. P. falciparum isolates containing the 
hrp2 gene may produce a false-negative RDT if the par-
asite density is below the threshold for RDT detection. 
Although this study lacks quantitative data on parasite 
density, a positive pLDH RDT may provide a crude esti-
mate of the parasite density (≥200–1000) parasites per 
microlitre [22]. Because HRP2-based RDTs are more sen-
sitive than pLDH-based RDTs at low parasite densities, 
a positive pLDH RDT suggests the parasite density was 
at or above the threshold for HRP2 RDT detection [6, 7, 
23, 24]. Conversely, microscopy positive/pLDH negative 
P. falciparum samples may reflect low density infections.
In this study, P. falciparum infections with parasite den-
sities below the threshold for detection may be respon-
sible for many of the false-negative RDTs. Of the 106 P. 
falciparum isolates with false-negative HRP2 RDTs and 
the hrp2 gene (confirmed by PCR), most (77%) were neg-
ative by pLDH RDT. Additionally, in Kibirizi, the propor-
tion of microscopy positive/pLDH RDT negative samples 
increased as the slide positivity rate fell (Fig.  6). The 
proportion of microscopy positive/pLDH negative sam-
ples rose from 13.9% (95% CI 12.7–16.0) during April to 
August 2014 to 38.6% (95% CI 32.1–45.6) during Decem-
ber 2014 to April 2015. This increase in the proportion 
of microscopy positive/pLDH negative samples may 
reflect an increase in the proportion of low density infec-
tions. Thus, the pLDH RDT data suggest that a decline 
in parasite density may have contributed to the decrease 
in HRP2 RDT sensitivity as malaria control improved in 
Kibirizi.
Fig. 6 pLDH RDT results for microcopy positive samples in Kibirizi. 
Of the 1778 microscopy positive samples from Kibirizi, 1447 samples 
were positive by the pLDH RDT (light blue bars) and 331 samples were 
negative by the pLDH RDT (black bars). Improved malaria control was 
associated with an increased in the proportion of the microscopy 
positive samples that were negative by the pLDH RDT
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Other potential causes for false-negative RDTs which 
were not examined in this study include partial deletions 
of the hrp2 gene, prozone effects due to excess antigen, 
sequence variability of P. falciparum hrp2 and circulating 
antibodies to HRP2 which have been reported to inter-
fere with RDT detection of HRP2 [11, 25–28]. While the 
primers used in this study amplified only exon 2 of the 
hrp2 gene, the hrp2 gene is also known to have chromo-
somal breaking points outside exon 2 [28].
There have been several reports of prozone-like effects 
with HRP2-based RDTs in patients with hyperparasitae-
mia. Although the mechanism of prozone-like effects for 
antigen detection tests is not well defined, one plausible 
explanation is that the amount of antigen may exceed 
the binding capacity of the dye-labelled antibodies used 
for antigen detection. In this situation, unlabelled target 
antigen reaches the test strip and saturates the binding 
capacity of the capture antibodies affixed to the test strip. 
As a result, antigen captured by dye-labelled antibodies 
may be unable to bind to the test strip to form a visible 
band [29]. However, false-negative HRP2 test lines attrib-
uted to the prozone effect have been described only in 
samples with ≥288,000 parasites/µL [30, 31]. While this 
study lacks data on parasite density, results of previous 
studies suggest that hyperparasitaemia is unlikely to have 
been a significant cause of false-negative RDTs in this 
study [31].
Of the 343 samples with false-negative HRP2 RDTs 
that were tested by PCR, 21 were negative by PCR for 
both hrp2 and 18S rRNA of the four Plasmodium para-
sites known to cause human infection. Sub-optimal PCR 
sensitivity may have occurred as a result of inadequate 
DNA sample, degradation of DNA sample, presence of 
PCR inhibitors and deletion or mutation of the targeted 
DNA [20]. Other possible explanations for these dis-
crepancies include false-positive microscopy results and 
pLDH RDT cross-reactivity with other infectious agents, 
such as African trypanosomes [32].
Importantly, there is potential for confusion about the 
RDT used in this study because Premier Medical Cor-
poration Ltd. submitted two different products with the 
name “First Response® Malaria Ag. pLDH/HRP2 Combo 
Card Test” to WHO for testing. The RDT used in this 
study, catalogue number I16FRC, was tested in rounds 
1, 2 and 5. However, a different product was tested in 
round 6 (catalogue number PI16FRC). Product I16FRC 
did not meet WHO recommended procurement crite-
ria during round 5 of WHO RDT lot testing because the 
panel detection score (PDS) for P. vivax at 200 parasites 
per microlitre was 74.5 (below the WHO criterion of 
≥75). In contrast, product I16FRC had a satisfactory PDS 
score of 85.0 for P. falciparum (please note that PDS is 
not equivalent to sensitivity) [6]. These data are available 
at: http://www.rdt-interactive-guide.org/ [33]. Because 
P. falciparum is the predominant species in Rwanda, the 
marginally low sensitivity of this RDT for P. vivax would 
not be expected to have a significant impact of the find-
ing of this study [5].
Finally, the authors recognize the lack of testing for 
additional single-copy genes is a theoretical limitation 
because the reported sensitivity of PCR is greater for 
multi-copy genes (18S rRNA) than single copy genes 
(hrp2) (1 vs 10–100 parasite per microlitre) [34]. How-
ever, several factors suggest the parasite densities of the 
P. falciparum samples that were negative by PCR for hrp2 
were above the threshold for detection by PCR for single-
copy genes: all patients had symptoms consistent with 
malaria infection, DNA was extracted within 3 months of 
sample collection and most P. falciparum isolates with-
out the hrp2 gene were detected by the pLDH RDT. Most 
symptomatic individuals in malaria-endemic areas have 
parasite densities ≥1000 parasites per microlitre [35] and 
prompt extraction of DNA limits the time for DNA deg-
radation which may disproportionately reduce the sensi-
tivity of PCR for single-copy genes. Additionally, based 
on the results from round 5 of WHO RDT quality testing, 
a positive pLDH RDT suggests the parasite density was 
above the threshold for detection by PCR for single-copy 
genes (≥200 parasites per microlitre). The pLDH RDT 
of the First Response® Malaria pLDH/HRP2 Combo test 
(catalogue number I16FRC) had a sensitivity of 31% for 
wild-type (clinical) P. falciparum smear-positive samples 
with 200 parasites per microlitre. In contrast, with para-
site densities of 2000 per microlitre, the sensitivity of the 
pLDH RDT was 100% [22].
Ultimately, the factors driving the decline in RDT 
sensitivity as malaria control improves are not clear. If 
parasite density declines as malaria control improves, 
the decrease in RDT sensitivity could be driven in part 
by an increase in the number of infections with para-
site densities below the RDT threshold for detection. In 
addition, there are concerns that hrp2-negative parasites 
may have an increased impact on RDT performance as 
malaria control improves [10, 11]. Conversely, in high 
transmission settings, hrp2 negative parasites may have 
less impact on RDT sensitivity because individuals are 
commonly infected with more than one P. falciparum 
parasite strain (genotype) and the RDT will yield a true-
positive result if any one parasite (genotype) is hrp2-
positive [10]. However, the number of parasite genotypes 
infecting individual subjects, the multiplicity of infection 
(MOI), declines as malaria control improves. Conversely, 
individuals infected by only a single parasite genotype 
negative for the hrp2 gene will produce false-negative 
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results when tested with an HRP2-based RDT [10]. In 
the present study, the decrease in HRP2 RDT sensitiv-
ity as malaria control improved was not associated with 
an increased frequency of hrp2-negative P. falciparum 
isolates. However, it may have been associated with an 
increase in the frequency of low density infections.
Conclusions
This study provides new information on the performance 
of RDTs in Rwanda and supports previously raised con-
cerns that the sensitivity of HRP2 RDTs may decline as 
malaria control improves. In addition, the results of this 
study suggest that the use of three-band RDTs (HRP2, 
pLDH and control bands) may improve sensitivity with-
out decreasing specificity. This study also found that P. 
falciparum isolates lacking the hrp2 gene are an impor-
tant source of false-negative HRP2 RDTs in Rwanda. 
Further investigations are warranted to better define the 
prevalence of these isolates and the factors responsi-
ble for the decline in RDT sensitivity as malaria control 
improves.
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